To date, total serum IgE is approved as the biomarker for determining eligibility in severe asthma patients for omalizumab (a humanized recombinant monoclonal antibody with binding specificity at the FcεRI binding site of IgE) treatment [19]. This evidence concerns the gene IGHE and asthma.